- Conditions
- Pneumonia, Influenza, Varicella Zoster, Meningitis, COVID-19, Vaccine Hesitancy
- Interventions
- Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
- Behavioral
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 372
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Breast Cancer, Lung Cancer, Melanoma (Skin)
- Interventions
- COVID-19 Vaccine
- Biological
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- COVID-19 Immunization, Influenza Immunization
- Interventions
- RIV (recombinant influenza vaccine), rC19 (dose 1), RIV + rC19 (dose 1), RIV + rC19 (dose 2), RIV + rC19 (dose 3), RIV + rC19 (dose 4), Placebo (0.9% NaCl)
- Biological · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 980 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Cerritos, California • Vista, California + 9 more
- Conditions
- SARS CoV 2 Infection, COVID-19
- Interventions
- Pfizer/BioNTech (BNT162b2), Moderna
- Biological
- Lead sponsor
- DHR Health Institute for Research and Development
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Brownsville, Texas • Edinburg, Texas • Rio Grande City, Texas
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- Papillomavirus Infections, Coronavirus Disease (COVID-19)
- Interventions
- 9vHPV Vaccine, mRNA-1273 Vaccine
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 33 more
- Conditions
- Vaccine Hesitancy
- Interventions
- Multilevel Intervention
- Behavioral
- Lead sponsor
- San Diego State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- San Diego, California
- Conditions
- Influenza, COVID-19
- Interventions
- Provider communication training
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- COVID-19
- Interventions
- Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283
- Drug
- Lead sponsor
- Marcel Curlin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- COVID-19, SARS-CoV-2 Infection
- Interventions
- NVX-CoV2705
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years to 90 Years
- Enrollment
- 676 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Melrose Park, Illinois • Lenexa, Kansas + 7 more
- Conditions
- COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs
- Interventions
- COVID-19 Vaccine IVR Training, Control Condition
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8,959 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- SARS-CoV-2
- Interventions
- Not listed
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 50,000,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pregnancy
- Interventions
- Observational
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Durham, North Carolina + 1 more
- Conditions
- Trust
- Interventions
- RNA vaccine, 20% adoption rate, 40% adoption rate, 60% adoption rate, 80% adoption rate, Conventional vaccine, 0% adoption rate
- Other
- Lead sponsor
- National University of Singapore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35,180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Vaccination Refusal, COVID-19 Pandemic
- Interventions
- Doctor Videos, Sharing Videos, Sharing Videos (Influencers), Vaccine Ambassador, Video framing, Video order
- Behavioral
- Lead sponsor
- Massachusetts Institute of Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- COVID-19, Kidney Transplant
- Interventions
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 3 more
- Conditions
- Atopic Dermatitis
- Interventions
- Cetaphil Restoraderm, Standard of Care
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 1 Day to 3 Weeks
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Covid-19 Prevention
- Interventions
- Ad26.COV2.S, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,085 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- San Diego, California • Melbourne, Florida • Peoria, Illinois + 4 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, mRNA-1283, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
- Conditions
- COVID-19
- Interventions
- COVID Booster text messages
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19, Sars-CoV-2 Infection
- Interventions
- NVX-CoV2705, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 65 Years
- Enrollment
- 6,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 99
- States / cities
- Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
- Conditions
- COVID-19
- Interventions
- COVID Booster text messages
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,600,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hematologic Disorders and Bone Marrow Failure, Hematopoietic Stem Cell Transplantation (HSCT) or Cellular Therapy (CART)
- Interventions
- COVID-19 serology IgG
- Diagnostic Test
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan